Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Page 1
Violiza Inoa.
[No authors listed] [No authors listed] Lancet Neurol. 2024 May;23(5):462. doi: 10.1016/S1474-4422(24)00130-3. Lancet Neurol. 2024. PMID: 38631763 No abstract available.
Important lessons on healthcare from rare diseases.
The Lancet Neurology. The Lancet Neurology. Lancet Neurol. 2024 May;23(5):447. doi: 10.1016/S1474-4422(24)00136-4. Lancet Neurol. 2024. PMID: 38631752 No abstract available.
Dementia prevention: from idealism to realism.
Avan A, Hachinski V. Avan A, et al. Lancet Neurol. 2024 May;23(5):460. doi: 10.1016/S1474-4422(24)00133-9. Lancet Neurol. 2024. PMID: 38631760 No abstract available.
Felicia Bliss Axelrod: the dysautonomia pioneer.
Trinidad Herrero M. Trinidad Herrero M. Lancet Neurol. 2024 May;23(5):461. doi: 10.1016/S1474-4422(24)00131-5. Lancet Neurol. 2024. PMID: 38631761 No abstract available.
The African Stroke Organization Conference 2023.
Sarfo FS, Gebreyohanns M, Akinyemi R, Ebenezer AA, Ovbiagele B, Owolabi M; ASOC 2023 Planning Committee. Sarfo FS, et al. Lancet Neurol. 2024 May;23(5):459-460. doi: 10.1016/S1474-4422(24)00139-X. Lancet Neurol. 2024. PMID: 38631758 No abstract available.
Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial.
Tawil R, Wagner KR, Hamel JI, Leung DG, Statland JM, Wang LH, Genge A, Sacconi S, Lochmüller H, Reyes-Leiva D, Diaz-Manera J, Alonso-Perez J, Muelas N, Vilchez JJ, Pestronk A, Gibson S, Goyal NA, Hayward LJ, Johnson N, LoRusso S, Freimer M, Shieh PB, Subramony SH, van Engelen B, Kools J, Leinhard OD, Widholm P, Morabito C, Moxham CM, Cadavid D, Mellion ML, Odueyungbo A, Tracewell WG, Accorsi A, Ronco L, Gould RJ, Shoskes J, Rojas LA, Jiang JG. Tawil R, et al. Lancet Neurol. 2024 May;23(5):477-486. doi: 10.1016/S1474-4422(24)00073-5. Lancet Neurol. 2024. PMID: 38631764 Clinical Trial.
Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study.
Wisch JK, McKay NS, Boerwinkle AH, Kennedy J, Flores S, Handen BL, Christian BT, Head E, Mapstone M, Rafii MS, O'Bryant SE, Price JC, Laymon CM, Krinsky-McHale SJ, Lai F, Rosas HD, Hartley SL, Zaman S, Lott IT, Tudorascu D, Zammit M, Brickman AM, Lee JH, Bird TD, Cohen A, Chrem P, Daniels A, Chhatwal JP, Cruchaga C, Ibanez L, Jucker M, Karch CM, Day GS, Lee JH, Levin J, Llibre-Guerra J, Li Y, Lopera F, Roh JH, Ringman JM, Supnet-Bell C, van Dyck CH, Xiong C, Wang G, Morris JC, McDade E, Bateman RJ, Benzinger TLS, Gordon BA, Ances BM; Alzheimer's Biomarker Consortium-Down syndrome; Dominantly Inherited Alzheimer Network. Wisch JK, et al. Lancet Neurol. 2024 May;23(5):500-510. doi: 10.1016/S1474-4422(24)00084-X. Lancet Neurol. 2024. PMID: 38631766
18 results